PDCD1 and neoplasm: Despite preclinical studies suggesting promising results from anti-PD-1 alone and in combination with other treatments [26–28], clinical trials and retrospective studies assessing the efficacy of this treatment in recurrent tumours have shown limited improvement in survival for patients [23, 24, 29, 30].